292 related articles for article (PubMed ID: 1872661)
1. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group.
Vance ML; Harris AG
Arch Intern Med; 1991 Aug; 151(8):1573-8. PubMed ID: 1872661
[TBL] [Abstract][Full Text] [Related]
2. [Long-term treatment of acromegaly with the somatostatin analog octreotide (Sandostatin). On the predictive significance of acute tests].
Schmidt K; Althoff PH; Harris A; Hofmeister-Wagner W; Schifferdecker E; Schöffling K
Med Klin (Munich); 1990 Dec; 85(12):700-6. PubMed ID: 2128367
[TBL] [Abstract][Full Text] [Related]
3. [Experience in treating acromegalic patients with long-acting octreotide].
Szücs N; Mészáros J; Czirják S; Mondok A; Varga I; Gláz E
Orv Hetil; 2002 May; 143(19 Suppl):1066-70. PubMed ID: 12063862
[TBL] [Abstract][Full Text] [Related]
4. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
Quabbe HJ; Plöckinger U
J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
[TBL] [Abstract][Full Text] [Related]
5. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
Plöckinger U; Quabbe HJ
Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
[TBL] [Abstract][Full Text] [Related]
6. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
Jallad RS; Musolino NR; Kodaira S; Cescato VA; Bronstein MD
Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503
[TBL] [Abstract][Full Text] [Related]
7. Long-term treatment of acromegaly with a long-acting analogue of somatostatin, octreotide.
Page MD; Millward ME; Taylor A; Preece M; Hourihan M; Hall R; Scanlon MF
Q J Med; 1990 Feb; 74(274):189-201. PubMed ID: 2111918
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study.
Newman CB; Melmed S; Snyder PJ; Young WF; Boyajy LD; Levy R; Stewart WN; Klibanski A; Molitch ME; Gagel RF
J Clin Endocrinol Metab; 1995 Sep; 80(9):2768-75. PubMed ID: 7673422
[TBL] [Abstract][Full Text] [Related]
9. Medical management of acromegaly--what and when?
Melmed S
Acta Endocrinol (Copenh); 1993 Jul; 129 Suppl 1():13-7. PubMed ID: 8372605
[TBL] [Abstract][Full Text] [Related]
10. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial.
Colao A; Pivonello R; Rosato F; Tita P; De Menis E; Barreca A; Ferrara R; Mainini F; Arosio M; Lombardi G
Clin Endocrinol (Oxf); 2006 Mar; 64(3):342-51. PubMed ID: 16487447
[TBL] [Abstract][Full Text] [Related]
11. [Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide].
Laczi F; Magony S; Julesz J
Orv Hetil; 2002 May; 143(19 Suppl):1062-6. PubMed ID: 12063861
[TBL] [Abstract][Full Text] [Related]
12. Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly.
Turner HE; Thornton-Jones VA; Wass JA
Clin Endocrinol (Oxf); 2004 Aug; 61(2):224-31. PubMed ID: 15272918
[TBL] [Abstract][Full Text] [Related]
13. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
Jallad RS; Musolino NR; Salgado LR; Bronstein MD
Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
[TBL] [Abstract][Full Text] [Related]
14. The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly.
Gilbert JA; Miell JP; Chambers SM; McGregor AM; Aylwin SJ
Clin Endocrinol (Oxf); 2005 Jun; 62(6):742-7. PubMed ID: 15943838
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
Giusti M; Gussoni G; Cuttica CM; Giordano G
J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
[TBL] [Abstract][Full Text] [Related]
16. Octreotide long term treatment of acromegaly: effect of drug withdrawal on serum growth hormone/insulin-like growth factor-I concentrations and on serum gastrin/24-hour intragastric pH values.
Plöckinger U; Liehr RM; Quabbe HJ
J Clin Endocrinol Metab; 1993 Jul; 77(1):157-62. PubMed ID: 8325938
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety.
Ho KY; Weissberger AJ; Marbach P; Lazarus L
Ann Intern Med; 1990 Feb; 112(3):173-81. PubMed ID: 2404445
[TBL] [Abstract][Full Text] [Related]
18. Effective clinical response to long term octreotide treatment, with reduced serum concentrations of growth hormone, insulin-like growth factor-I, and the amino-terminal propeptide of type III procollagen in acromegaly.
Salmela PI; Juustila H; Pyhtinen J; Jokinen K; Alavaikko M; Ruokonen A
J Clin Endocrinol Metab; 1990 Apr; 70(4):1193-201. PubMed ID: 2180976
[TBL] [Abstract][Full Text] [Related]
19. Effects of octreotide on lipid metabolism in acromegaly.
Cohen R; Chanson P; Bruckert E; Timsit J; Legrand A; Harris AG; Guillausseau PJ; Warnet A; Lubetzki J
Horm Metab Res; 1992 Aug; 24(8):397-400. PubMed ID: 1526629
[TBL] [Abstract][Full Text] [Related]
20. Long-term effect of octreotide in acromegaly on insulin resistance.
Breidert M; Pinzer T; Wildbrett J; Bornstein SR; Hanefeld M
Horm Metab Res; 1995 May; 27(5):226-30. PubMed ID: 7642173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]